Previsioni di mercato dei servizi di farmacocinetica in Medio Oriente e Africa fino al 2031 - Analisi regionale - per tipo di farmaco (piccole molecole, grandi molecole e vaccini), tipo di servizio (studi ADME e umani preclinici, analisi e reporting PK/PD, simulazioni di dosaggio, analisi del rischio e altri), applicazione terapeutica (oncologia, malattie infettive, disturbi neurologici, malattie autoimmuni, disturbi ginecologici, malattie cardiovascolari, disturbi respiratori e altri) e utente finale (aziende farmaceutiche e biotecnologiche, organizzazioni di ricerca a contratto e altri)
La crescente prevalenza di malattie croniche e infettive rafforza il mercato dei servizi di farmacocinetica in Medio Oriente e Africa
La crescente prevalenza di malattie croniche come diabete, cancro e malattie autoimmuni è stata un fattore chiave per gli sforzi di sviluppo di farmaci in tutto il mondo. Secondo i dati del 2024 dell\'Organizzazione mondiale della sanità (OMS), circa 422 milioni di persone nel mondo soffrono di diabete e questi casi si riscontrano principalmente nei paesi a medio e basso reddito, causando circa 1,5 milioni di decessi ogni anno. Le aziende farmaceutiche sono in prima linea nello sviluppo di farmaci per il trattamento di varie malattie. Gli studi farmacocinetici sono essenziali per comprendere come questi farmaci si comportano nel corpo di un paziente analizzando il processo di assorbimento, distribuzione, metabolizzazione ed eliminazione (ADME) all\'interno del corpo umano. L\'assorbimento di un farmaco nella circolazione sistemica influenza la velocità e la concentrazione a cui un farmaco può raggiungere il sito di azione, ad esempio il plasma. I modelli di distribuzione del farmaco in tutto il corpo variano in base alle sue proprietà biochimiche e alla fisiologia corporea. Il metabolismo implica l\'elaborazione del farmaco da parte del corpo in composti successivi. Questa fase è fondamentale per convertire il farmaco in sostanze idrosolubili per renderle adatte alla clearance renale. Il metabolismo è anche importante per la conversione di profarmaci, come la codeina, in metaboliti attivi. L\'escrezione dei farmaci dal corpo è principalmente regolata dai reni; tuttavia, in diversi casi, i farmaci possono essere escreti tramite i polmoni, la pelle o il tratto gastrointestinale. Le dinamiche ADME definiscono la biodisponibilità dei farmaci nel corpo e le dosi di mantenimento dei farmaci vengono calcolate in base ai loro tempi di clearance (concentrazione plasmatica desiderata divisa per biodisponibilità). La comprensione dell\'autorizzazione consente ai professionisti di calcolare i dosaggi appropriati.
Gli studi farmacocinetici si concentrano sull\'ottimizzazione dei regimi di dosaggio dei farmaci nei soggetti dello studio per comprendere l\'efficacia e la sicurezza di un farmaco. Questi studi sono essenziali per garantire la sicurezza dei farmaci sviluppati per trattamenti a lungo termine, il che aiuta a valutare l\'idoneità e la stabilità delle formulazioni dei farmaci nella gestione delle malattie croniche. Quindi, il crescente peso delle malattie croniche e infettive sottolinea l\'importanza degli studi farmacocinetici per sviluppare trattamenti personalizzati sicuri ed efficaci.
Panoramica del mercato dei servizi di farmacocinetica in Medio Oriente e Africa
Il Sudafrica rappresenta la quota maggiore del mercato dei servizi di farmacocinetica in Medio Oriente e Africa. Il governo del Sudafrica ha iniziato a fornire incentivi agli investimenti, adottando misure per proteggere i diritti di proprietà intellettuale (PI), semplificando le norme fiscali e imponendo migliori politiche normative per attrarre investimenti esteri per alimentare in ultima analisi il panorama degli studi clinici nel paese. Nel 2019, un totale di circa 62,67 milioni di $ USA (1 miliardo di ZAR) è stato investito in studi imminenti e in corso. Nel periodo 2016-2021, circa 0,18 miliardi di $ USA (2,95 miliardi di ZAR) sono stati spesi da aziende farmaceutiche multinazionali innovative operanti in Sudafrica per supportare attività di ricerca clinica incentrate sulla risposta alle esigenze mediche insoddisfatte del Paese.
Il Sudafrica è il Paese economicamente più sviluppato del continente africano e ha stabilito standard normativi migliori per le sperimentazioni cliniche. Costi inferiori delle operazioni di ricerca clinica e un rischio minore di contenzioso rendono il Sudafrica un\'opzione interessante per le aziende straniere che esternalizzano le loro operazioni di ricerca clinica. Inoltre, il numero di sperimentazioni è aumentato grazie agli alti tassi di reclutamento e a un ambiente normativo migliorato nel Paese. Il Sudafrica riceve sostanziali sponsorizzazioni da aziende farmaceutiche innovative per condurre ricerche cliniche, senza segni di rallentamento. Pertanto, il progresso del settore della ricerca clinica rafforza la crescita del mercato dei servizi di farmacocinetica nel Paese.
Ricavi e previsioni del mercato dei servizi di farmacocinetica in Medio Oriente e Africa fino al 2031 (milioni di $ USA)
Segmentazione del mercato dei servizi di farmacocinetica in Medio Oriente e Africa
Il mercato dei servizi di farmacocinetica in Medio Oriente e Africa è suddiviso in tipo di farmaco, tipo di servizio, applicazione terapeutica, utente finale e paese.
In base al tipo di farmaco, il mercato dei servizi di farmacocinetica in Medio Oriente e Africa è suddiviso in piccole molecole, grandi molecole e vaccini. Il segmento delle piccole molecole ha detenuto la quota di mercato maggiore nel 2023.
In termini di tipo di servizio, il mercato dei servizi di farmacocinetica in Medio Oriente e Africa è suddiviso in studi ADME preclinici e sull\'uomo, analisi e reporting PK/PD, simulazioni di dosaggio, analisi del rischio e altri. Il segmento ADME preclinico e studi sull\'uomo ha detenuto la quota di mercato più grande nel 2023.
Per applicazione terapeutica, il mercato dei servizi di farmacocinetica in Medio Oriente e Africa è segmentato in oncologia, malattie infettive, disturbi neurologici, malattie autoimmuni, disturbi ginecologici, malattie cardiovascolari, disturbi respiratori e altri. Il segmento oncologico ha detenuto la quota di mercato più grande nel 2023.
Per utente finale, il mercato dei servizi di farmacocinetica in Medio Oriente e Africa è segmentato in aziende farmaceutiche e biotecnologiche, organizzazioni di ricerca a contratto e altri. Il segmento delle organizzazioni di ricerca a contratto ha detenuto la quota di mercato più grande nel 2023.
Per paese, il mercato dei servizi di farmacocinetica in Medio Oriente e Africa è segmentato in Sud Africa, Arabia Saudita, Emirati Arabi Uniti e resto del Medio Oriente e Africa. Il Sud Africa ha dominato la quota di mercato dei servizi di farmacocinetica in Medio Oriente e Africa nel 2023.
Charles River Laboratories International Inc; Eurofins Scientific SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; e SGS SA sono tra le aziende leader che operano nel mercato dei servizi di farmacocinetica in Medio Oriente e Africa.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Pharmacokinetics Services Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic and Infectious Diseases
4.1.2 Expanding Range of Application of Pharmacokinetic Studies
4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:
5. Pharmacokinetics Services Market - Middle East & Africa Analysis
5.1 Middle East & Africa Pharmacokinetics Services Market Overview
5.2 Middle East & Africa Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
6. Middle East & Africa Pharmacokinetics Services Market Analysis - by Drug Type
6.1 Overview
6.2 Small Molecule
6.2.1 Overview
6.2.2 Small Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
6.3.1 Overview
6.3.2 Large Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7. Middle East & Africa Pharmacokinetics Services Market Analysis - by Service Type
7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
7.2.1 Overview
7.2.2 Pre-Clinical ADME and Human Studies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
7.3.1 Overview
7.3.2 PK/PD Analysis and Reporting: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
7.4.1 Overview
7.4.2 Dosing Simulations: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
7.5.1 Overview
7.5.2 Risk Analysis: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. Middle East & Africa Pharmacokinetics Services Market Analysis - by Therapeutic Application
8.1 Oncology
8.1.1 Overview
8.1.2 Oncology: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
8.3.1 Overview
8.3.2 Neurological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
8.4.1 Overview
8.4.2 Autoimmune Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
8.5.1 Overview
8.5.2 Gynecological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
8.6.1 Overview
8.6.2 Cardiovascular Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Respiratory Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. Middle East & Africa Pharmacokinetics Services Market Analysis - by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
9.2.1 Overview
9.2.2 Contract Research Organization: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. Middle East & Africa Pharmacokinetics Services Market - Country Analysis
10.1 Middle East and Africa
10.1.1 Middle East & Africa Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
10.1.1.1 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.3 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.1.4 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.1.5 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.1.6 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.2 South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.3 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.2.4 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.2.5 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.2.6 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.3 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.3 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.3.4 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.3.5 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.3.6 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.4 Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.3 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.4.4 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.4.5 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.4.6 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
11. Company Profile
11.1 Charles River Laboratories International Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eurofins Scientific SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Certara Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.4 Parexel International Corp
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Thermo Fisher Scientific Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Allucent
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 PACIFIC BIOLABS
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 SGS SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms for Pharmacokinetic Services Market
?
List of Tables
Table 1. Middle East & Africa Pharmacokinetics Services Market Segmentation
Table 2. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 3. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 4. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 5. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 6. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 7. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 8. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 9. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 10. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 11. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 12. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 13. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 14. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 15. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 16. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 17. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 18. Glossary of Terms
?
List of Figures
Figure 1. Middle East & Africa Pharmacokinetics Services Market Segmentation, by Country
Figure 2. Middle East & Africa Pharmacokinetics Services Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 5. Middle East & Africa Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
Figure 6. Small Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Large Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Vaccines: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Middle East & Africa Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
Figure 10. Pre-Clinical ADME and Human Studies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. PK/PD Analysis and Reporting: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. Dosing Simulations: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Risk Analysis: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Middle East & Africa Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
Figure 16. Oncology: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. Infectious Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Neurological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Autoimmune Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Gynecological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Cardiovascular Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Respiratory Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Middle East & Africa Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
Figure 25. Pharmaceutical and Biotechnology Companies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 26. Contract Research Organization: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Middle East & Africa Pharmacokinetics Services Market by Key Countries - Revenue 2023 (US$ Million)
Figure 29. Middle East & Africa Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 30. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 31. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 32. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 33. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
- Allucent
- Certara Inc.
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- PACIFIC BIOLABS
- Parexel International Corp
- SGS SA
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa pharmacokinetics services market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Middle East & Africa pharmacokinetics services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.